Table 2.
Main baseline characteristics of patients hospitalized in France for COVID-19 (from 1 March 2020 to 30 April 2020) according to the presence of cancer and cancer types.
| Hematological Cancer | Solid Metastatic Cancer | Solid Cancer without Metastasis | Without Cancer | p-Value * | |
|---|---|---|---|---|---|
| Number of patients | 1389 | 1775 | 2558 | 83,329 | |
| Male gender (n, %) | 797 (57.4) ** | 998 (56.2) ** | 1627 (63.6) ** | 43,787 (52.6) | <0.01 |
| Age | <0.01 | ||||
| Mean +/− std | 72 +/− 15 ** | 70 +/− 13 ** | 74 +/− 13 ** | 65 +/− 20 | |
| Med (Q1–Q3) | 74 (65–83) | 71 (62–80) | 75 (66–84) | 67 (51–81) | |
| Social deprivation score | |||||
| Mean +/− std | −0.44 +/− 1.81 $ | −0.45 +/− 1.72 $ | −0.44 +/− 1.79 $ | −0.26 +/− 1.78 | <0.01 |
| Med [Q1–Q3] | −0.17 [−1.41–0.82] | −0.20 [−1.40–0.75] $ | −0.20 [−1.38–0.78] $ | −0.14 [−1.22–0.93] | |
| Lowest (<−1.233) | 383 (27.3) ** | 504 (28.1) ** | 702 (26.9) ** | 19,661 (24.8) | <0.01 |
| Second ([−1.23; −0.146]) | 332 (23.7) | 443 (24.7) | 672 (25.7) | 19,621 (24.8) | |
| Third ([−0.146; −0.917]) | 369 (26.3) | 463 (25.8) | 658 (25.2) | 19,983 (25.2) | |
| Highest (≥0.917) | 319 (22.7) $ | 382 (21.3) $ | 582 (22.3) $ | 19,980 (25.2) | |
| Hospital type admission | |||||
| Public | 1288 (92.7) ** | 1492 (84.1) $ | 2259 (88.3) | 74,248 (89.1) | <0.01 |
| Private | 101 (7.3) $ | 283 (15.9) ** | 299 (11.7) | 9081 (10.9) | |
| Comorbidities | |||||
| Hypertension | 514 (37.0) ** | 502 (28.3) $ | 1016 (39.7) ** | 27,406 (32.9) | <0.01 |
| Dementia | 81 (5.8) $ | 59 (3.3) $ | 213 (8.3) | 6361 (7.6) | <0.01 |
| HIV | 9 (0.7) | 6 (0.3) | 16 (0.6) | 400 (0.5) | 0.39 |
| Heart failure | 161 (11.6) ** | 128 (7.2) | 246 (9.6) ** | 6553 (7.9) | <0.01 |
| Chronic respiratory disease | 22 (1.6) | 37 (2.1) | 49 (1.9) | 1313 (1.6) | 0.10 |
| Chronic kidney disease | 161 (11.6) ** | 103 (5.8) $ | 303 (11.9) ** | 6838 (8.2) | <0.01 |
| Cirrhosis | 10 (0.7) | 23 (1.3) ** | 90 (3.5) ** | 584 (0.7) | <0.01 |
| Diabetes | 237 (17.1) | 301 (17.0) $ | 587 (23.0) ** | 15,841 (19.0) | < 0.01 |
| Peripheral vascular disease | 47 (3.4) | 67 (3.8) | 159 (6.2) ** | 2572 (3.1) | <0.01 |
| Obese or overweight | 129 (9.3) $ | 73 (4.1) $ | 205 (8.0) $ | 9691 (11.6) | <0.01 |
| Obese | 104 (7.5) $ | 66 (3.7) $ | 170 (6.7) $ | 8257 (9.9) | <0.01 |
| Dyslipidemia | 96 (6.9) ** | 78 (4.4) | 173 (6.8) ** | 4103 (4.9) | <0.01 |
| Deficiency Anemia | 82 (5.9) ** | 73 (4.1) | 159 (6.2) ** | 3162 (3.8) | <0.01 |
| COPD | 68 (4.9) | 116 (6.5) ** | 250 (9.8) ** | 4385 (5.3) | <0.01 |
| Pulmonary bacterial infection | 137 (9.9) ** | 98 (5.5) $ | 177 (6.9) | 5845 (7.0) | 0.05 |
| Complications | |||||
| Acute respiratory failure | 476 (34.3) ** | 519 (29.2) ** | 753 (29.4) ** | 22,436 (26.9) | <0.01 |
| Pulmonary embolism | 59 (4.3) | 86 (4.9) ** | 105 (4.1) ** | 2813 (3.4) | <0.01 |
| Venous thrombosis | 89 (6.5) ** | 115 (6.5) ** | 144 (5.6) ** | 3988 (4.8) | <0.01 |
| Septic shock | 59 (5.0) ** | 26 (1.5) $ | 86 (3.3) | 2356 (2.8) | <0.01 |
| Myocardial infarction | 10 (0.7) | 2 (0.1) $ | 11 (0.4) | 531 (0.6) | 0.01 |
| Atrial fibrillation | 239 (17.2) ** | 217 (12.2) | 440 (17.2) ** | 10,155 (12.2) | <0.01 |
| Stroke | 12 (0.9) | 15 (0.9) | 37 (1.5) | 997 (1.2) | 0.20 |
| Hemorrhagic stroke | 5 (0.4) | 6 (0.3) | 6 (0.2) | 234 (0.3) | 0.82 |
| Ischemic stroke | 5 (0.4) | 6 (0.3) $ | 24 (0.9) | 674 (0.8) | 0.07 |
| Transient Ischemic Attack | 2 (0.1) | 5 (0.3) | 8 (0.3) | 146 (0.2) | 0.17 |
| Acute kidney failure | 157 (11.3) ** | 107 (6.0) | 202 (7.9) * | 5258 (6.3) | <0.01 |
| Intensive care support | 345 (24.8) ** | 157 (8.9) $ | 373 (14.6) $ | 13,655 (16.4) | <0.01 |
| In-hospital death | 470 (33.8) ** | 693 (39.0) ** | 690 (27.0) ** | 13,057 (15.7) | <0.01 |
* p-value related to the comparison of the three groups (solid metastatic cancer, solid cancer without metastasis and without cancer). ** significantly higher in the cancer group compared to the non-cancer group (p < 0.05). $ significantly lower in the cancer group compared to the non-cancer group (p < 0.05).